223 related articles for article (PubMed ID: 10952579)
21. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis.
Kretschmar M; Nichterlein T; Hannak D; Hof H
Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344
[TBL] [Abstract][Full Text] [Related]
22. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.
Espuelas MS; Legrand P; Campanero MA; Appel M; Chéron M; Gamazo C; Barratt G; Irache JM
J Antimicrob Chemother; 2003 Sep; 52(3):419-27. PubMed ID: 12888593
[TBL] [Abstract][Full Text] [Related]
23. Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral
Zhou L; Zhang P; Chen Z; Cai S; Jing T; Fan H; Mo F; Zhang J; Lin R
Int J Nanomedicine; 2017; 12():4269-4283. PubMed ID: 28652732
[TBL] [Abstract][Full Text] [Related]
24. NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency.
Burgess BL; He Y; Baker MM; Luo B; Carroll SF; Forte TM; Oda MN
Int J Nanomedicine; 2013; 8():4733-43. PubMed ID: 24379661
[TBL] [Abstract][Full Text] [Related]
25. Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis.
Garcia A; Adler-Moore JP; Proffitt RT
Antimicrob Agents Chemother; 2000 Sep; 44(9):2327-32. PubMed ID: 10952575
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
Andes D; Safdar N; Marchillo K; Conklin R
Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
[TBL] [Abstract][Full Text] [Related]
27. Superior efficacy of liposomal amphotericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic mice.
van Etten EW; Snijders SV; van Vianen W; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 1998 Sep; 42(9):2431-3. PubMed ID: 9736577
[TBL] [Abstract][Full Text] [Related]
28. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis.
Lu R; Hollingsworth C; Qiu J; Wang A; Hughes E; Xin X; Konrath KM; Elsegeiny W; Park YD; Atakulu L; Craft JC; Tramont EC; Mannino R; Williamson PR
mBio; 2019 May; 10(3):. PubMed ID: 31138748
[No Abstract] [Full Text] [Related]
30. [Treatment of experimental murine candidiasis with liposome-encapsulated amphotericin B].
Sasahara T
Kansenshogaku Zasshi; 1989 Dec; 63(12):1301-7. PubMed ID: 2621383
[TBL] [Abstract][Full Text] [Related]
31. Hamycin treatment of candidiasis in normal and diabetic rats.
Dhuley JN
FEMS Immunol Med Microbiol; 1999 Nov; 26(2):175-80. PubMed ID: 10536305
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits.
Groll AH; Petraitis V; Petraitiene R; Field-Ridley A; Calendario M; Bacher J; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 1999 Oct; 43(10):2463-7. PubMed ID: 10508025
[TBL] [Abstract][Full Text] [Related]
33. Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits.
Chemlal K; Saint-Julien L; Joly V; Farinotti R; Seta N; Yeni P; Carbon C
Antimicrob Agents Chemother; 1996 Jan; 40(1):263-6. PubMed ID: 8787921
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice.
Gondal JA; Swartz RP; Rahman A
Antimicrob Agents Chemother; 1989 Sep; 33(9):1544-8. PubMed ID: 2684010
[TBL] [Abstract][Full Text] [Related]
35. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.
Louie A; Liu W; Miller DA; Sucke AC; Liu QF; Drusano GL; Mayers M; Miller MH
Antimicrob Agents Chemother; 1999 Dec; 43(12):2831-40. PubMed ID: 10582868
[TBL] [Abstract][Full Text] [Related]
36. Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes).
Kretschmar M; Amselem S; Zawoznik E; Mosbach K; Dietz A; Hof H; Nichterlein T
Mycoses; 2001; 44(7-8):281-6. PubMed ID: 11714063
[TBL] [Abstract][Full Text] [Related]
37. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
Tiphine M; Letscher-Bru V; Herbrecht R
Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
[TBL] [Abstract][Full Text] [Related]
38. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis.
Adler-Moore JP; Olson JA; Proffitt RT
J Antimicrob Chemother; 2004 Dec; 54(6):1096-102. PubMed ID: 15509617
[TBL] [Abstract][Full Text] [Related]
39. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice.
van Etten EW; van den Heuvel-de Groot C; Bakker-Woudenberg IA
J Antimicrob Chemother; 1993 Nov; 32(5):723-39. PubMed ID: 8125837
[TBL] [Abstract][Full Text] [Related]
40. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B.
Oda MN; Hargreaves PL; Beckstead JA; Redmond KA; van Antwerpen R; Ryan RO
J Lipid Res; 2006 Feb; 47(2):260-7. PubMed ID: 16314670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
